RxDoctor Payments Data

Muir Blochberger, PA

Physician Assistant · du Bois, PANPI 1750763413

Payments from drug & device makers

$7,947in general payments, 2019–2025

Across 448 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$608
  • Daiichi Sankyo Inc.$589
  • Incyte Corporation$569
  • Johnson & Johnson$472
  • Merck$399
  • AbbVie$352
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,68897%
  • Education$2603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis36$608
Daiichi Sankyo Inc.31$589
Incyte Corporation31$569
Johnson & Johnson(2 entities)25$472
Merck22$399
AbbVie22$352
AstraZeneca(2 entities)18$346
Takeda Pharmaceuticals U.S.A., Inc.20$333
Exelixis Inc.15$304
GSK13$248
Pfizer17$234
Amgen10$230
Lilly USA, LLC10$223
Eisai Inc.9$172
Bristol Myers Squibb11$170
E.r. Squibb & Sons, L.L.C.10$165
Rigel Pharmaceuticals, Inc.12$154
Genentech USA, Inc.9$150
Sanofi6$132
Ipsen Biopharmaceuticals, Inc7$126
Array Biopharma Inc8$115
AVEO Pharmaceuticals, Inc.6$111
ADC Therapeutics America, Inc.6$110
Regeneron Healthcare Solutions, Inc.5$101
Sumitomo Pharma America, Inc.6$98
Seagen Inc.6$91
Pharmacosmos Therapeutics Inc.4$91
Astellas Pharma US Inc5$88
Blueprint Medicines Corporation5$87
Tersera Therapeutics LLC5$87
Pharmaessentia USA Corporation3$79
Karyopharm Therapeutics Inc.4$67
Jazz Pharmaceuticals Inc.3$59
Beigene USA, Inc.4$55
Taiho Oncology, Inc.3$53
Deciphera Pharmaceuticals Inc.3$50
Beone Medicines USA, Inc.3$47
EMD Serono, Inc.2$47
Stemline Therapeutics Inc.3$46
Syndax Pharmaceuticals, Inc.2$40
Tolmar, Inc.2$36
Springworks Therapeutics, Inc.2$35
Bayer2$33
Morphosys, US Inc.2$31
Gilead2$30
Sobi, Inc2$29
Puma Biotechnology, Inc.2$26
Tactile Systems Technology Inc2$25
Myriad Genetic Laboratories, Inc.1$22
Kyowa Kirin, Inc.1$20
Boehringer Ingelheim1$20
Servier Pharmaceuticals LLC1$19
G1 Therapeutics, Inc.1$18
Coherus Oncology, Inc.1$17
Geron Corporation1$17
Foundation Medicine, Inc.1$17
Genmab U.S., Inc.1$15
Novocure Inc.1$15
Pharmaand GmbH1$14
Acceleron Pharma, Inc.1$13

How this compares

$7,947 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$33,555
Medicare patients
202
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib39$624,983
TasignaNilotinib Hcl13$260,279
EliquisApixaban18$10,274
Anastrozole112$2,407
Exemestane16$2,158
Dexamethasone33$717
Hydroxyurea18$470
Prochlorperazine Maleate29$290
Lidocaine-PrilocaineLidocaine/Prilocaine23$288
Letrozole18$260
Ondansetron OdtOndansetron12$209
Acyclovir24$199
Bicalutamide12$183
Doxycycline Hyclate11$162
Allopurinol35$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTasigna$608$260,27913 claims
PfizerEliquis$234$10,27418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in du Bois

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →